A novel histone deacetylase inhibitor augments tamoxifen-mediated attenuation of breast carcinoma growth.
Int J Cancer
; 125(2): 483-7, 2009 Jul 15.
Article
em En
| MEDLINE
| ID: mdl-19330834
ABSTRACT
Earlier we generated novel derivatives of the hydroxamate-based histone deacetylase inhibitor (HDACi), Oxamflatin (Ox), which demonstrate considerable HDACi activity. Here the effects of one such derivative, Metacept-1 (MCT-1), alone or in combination with tamoxifen on mammary tumour growth have been assessed in a syngeneic orthotopic model. MCT-1 alone resulted in a trend towards inhibition of growth of 4T1.2 mammary tumours. Since the combination of MCT-1 and tamoxifen up-regulates estrogen receptor expression in 4T1.2 cells in vitro, we tested this combination and found a significant reduction in primary tumour growth over tamoxifen treatment alone. Taken together, these observations suggest that the novel HDACi MCT-1 may warrant further exploration in the treatment of estrogen receptor positive breast carcinoma, particularly when used in combination with conventional agents such as tamoxifen.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Tamoxifeno
/
Divisão Celular
/
Antineoplásicos Hormonais
/
Inibidores Enzimáticos
/
Inibidores de Histona Desacetilases
/
Neoplasias Mamárias Experimentais
Limite:
Animals
Idioma:
En
Revista:
Int J Cancer
Ano de publicação:
2009
Tipo de documento:
Article
País de afiliação:
Austrália